PNV Stock Overview
Develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.08 |
| 52 Week High | AU$2.52 |
| 52 Week Low | AU$1.10 |
| Beta | 1.61 |
| 1 Month Change | 0.97% |
| 3 Month Change | 2.97% |
| 1 Year Change | 48.04% |
| 3 Year Change | -22.10% |
| 5 Year Change | 92.59% |
| Change since IPO | 940.00% |
Recent News & Updates
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
May 08
When Should You Buy PolyNovo Limited (ASX:PNV)?
Feb 28Recent updates
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
May 08When Should You Buy PolyNovo Limited (ASX:PNV)?
Feb 28Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S
Feb 02PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jan 08Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?
Sep 22When Should You Buy PolyNovo Limited (ASX:PNV)?
Jun 26Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?
May 30Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price
Apr 18Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?
Mar 23Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?
Feb 05Returns At PolyNovo (ASX:PNV) Are On The Way Up
Nov 16PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price
Nov 01What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?
Jul 29PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital
Jun 15Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)
May 16We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt
Apr 28There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital
Mar 07Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?
Dec 13PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why
Oct 19Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?
May 08News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat
Feb 27Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts
Feb 25Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?
Feb 17These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat
Jan 14
Breakeven Is Near for PolyNovo Limited (ASX:PNV)
Dec 28Shareholder Returns
| PNV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -7.1% | 2.2% | 0.7% |
| 1Y | 48.0% | 18.2% | 7.8% |
Return vs Industry: PNV exceeded the Australian Medical Equipment industry which returned 18.2% over the past year.
Return vs Market: PNV exceeded the Australian Market which returned 7.8% over the past year.
Price Volatility
| PNV volatility | |
|---|---|
| PNV Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 9.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PNV has not had significant price volatility in the past 3 months.
Volatility Over Time: PNV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 237 | Swami Raote | www.polynovo.com |
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.
PolyNovo Limited Fundamentals Summary
| PNV fundamental statistics | |
|---|---|
| Market cap | AU$1.44b |
| Earnings (TTM) | AU$1.59m |
| Revenue (TTM) | AU$83.47m |
900.4x
P/E Ratio17.2x
P/S RatioIs PNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNV income statement (TTM) | |
|---|---|
| Revenue | AU$83.47m |
| Cost of Revenue | AU$14.09m |
| Gross Profit | AU$69.38m |
| Other Expenses | AU$67.78m |
| Earnings | AU$1.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0023 |
| Gross Margin | 83.12% |
| Net Profit Margin | 1.91% |
| Debt/Equity Ratio | 3.4% |
How did PNV perform over the long term?
See historical performance and comparison